All In Biotech

Drug Trial Radar · NCT04360187

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CRISABOROLE OINTMENT, 2% IN CHINESE AND JAPANESE PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS

Last checked: Nov 20, 2026Latest source record: Jun 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 391 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

391

Actual

Start

Jul 27, 2020

Primary completion

Sep 8, 2021

Study completion Sep 8, 2021

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 3, randomized, double blind and vehicle study to evaluate the efficacy and safety of Crisaborole ointment, 2% in Chinese and Japanese subjects with mild to moderate atopic dermatitis involving at least 5% treatable BSA. Eligible subjects will be randomized in a 2:1 ratio to one of 2 treatment groups (Crisaborole BID, Vehicle BID, respectively).

Conditions

  • Atopic Dermatitis

Interventions

  • Crisaborole OintmentDrug

    Crisaborole ointment 2%

  • Crisaborole Placebo VehicleDrug

    Placebo for crisaborole ointment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 29Time frame: Baseline, Day 29
  2. Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: Baseline up to Day 60
  3. Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 29
  4. Percentage of Participants With Clinically Significant Changes From Baseline in Vital SignsTime frame: Baseline up to Day 29

Locations

39 sites in 3 countries. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • The Second Affiliated Hospital of Army Medical University,PLA

    Chongqing, China

  • Children's Hospital of Shanghai

    Shanghai, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shenzhen Children's Hospital

    Shenzhen, Guangdong, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First hospital of Jilin University

    Changchun, Jilin, China

  • Shandong Provincial Institute of Dermatology and Venereology & Shandong Provincial Hospital for Skin

    Jinan, Shandong, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Hangzhou Third Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital/Dermatology Department

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

  • The first Affiliated hospital of Wenzhou medical University

    Wenzhou, Zhejiang, China

  • Hoshikuma Dermatology・Allergy Clinic

    Fukuoka, Japan

  • Miyata Dermatology Clinic

    Matsudo, Chiba, Japan

  • Shirao Clinic of Pediatrics and Pediatric Allergy

    Hiroshima, Hiroshima, Japan

  • Motomachi Dermatology Clinic

    Asahikawa-shi, Hokkaido, Japan

  • Chitose dermatology and plastic surgery clinic

    Chitose Shi, Hokkaido, Japan

  • Takagi Dermatological Clinic

    Obihiro, Hokkaido, Japan

  • Yoshimura Child Clinic

    Akashi, Hyōgo, Japan

  • Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic

    Kobe, Hyōgo, Japan

  • Nomura Dermatology Clinic

    Yokohama, Kanagawa, Japan

  • Noguchi Dermatology Clinic

    Kamimashiki-gun, Kumamoto, Japan

  • Yoshioka Dermatology Clinic

    Neyagawa, Osaka, Japan

  • Kume Clinic

    Sakai, Osaka, Japan

  • Mildix Skin Clinic

    Adachi-ku, Tokyo, Japan

  • Yoga Allergy Clinic

    Setagaya-ku, Tokyo, Japan

  • Sugamo Kobayashi Derma Clinic

    Toshima-Ku, Tokyo, Japan

  • Sugamo Sengoku Dermatology

    Toshima-Ku, Tokyo, Japan

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.